Core Viewpoint - The article discusses the initiation of a Phase III clinical trial for HB0025, a drug developed by Huahai Pharmaceutical's subsidiary, Huatai, aimed at treating advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy [1][4]. Group 1: Clinical Trial Details - The clinical trial, registered under CTR20260016, is a randomized, double-blind, multi-center study named DUALIGHT-02, which will evaluate the efficacy and safety of HB0025 in comparison to pembrolizumab combined with chemotherapy [2][4]. - The trial aims to enroll 480 participants in China, with the primary endpoint being progression-free survival (PFS) assessed by blinded independent central review (BICR) according to RECIST v1.1 criteria [4]. - The drug HB0025 is an innovative PD-L1/VEGF dual-specific fusion protein designed to target both tumor immune evasion pathways and tumor angiogenesis pathways, providing a dual mechanism of action [4]. Group 2: Drug Development Status - HB0025 has reached Phase III clinical trials in China, while it is currently in Phase II globally for various cancers, including hepatocellular carcinoma and triple-negative breast cancer [5][9]. - The drug has shown promising results in earlier trials, with an objective response rate (ORR) of 83.3% in the squamous NSCLC cohort and 100% in the high PD-L1 expressing group, along with a disease control rate (DCR) of 95.8% [7]. - Huahai Pharmaceutical has invested approximately 326 million yuan in the development of HB0025 [9].

Core Viewpoint - The company, Huahai Pharmaceutical, has announced the initiation of Phase III clinical trials for HB0025, a novel PD-L1/VEGF dual-specific fusion protein aimed at treating squamous and non-squamous non-small cell lung cancer [1][2]. Group 1: Clinical Development - The company’s subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., will officially start the Phase III clinical trial for HB0025 after discussions with the National Medical Products Administration [1]. - HB0025 is designed to target both PD-L1 and VEGF pathways, enhancing anti-tumor mechanisms through dual action on immune evasion and tumor angiogenesis [1][2]. - The Phase III trials will include two confirmatory studies, which are expected to provide new first-line treatment options for advanced non-small cell lung cancer patients, regardless of PD-L1 expression levels [2]. Group 2: Competitive Landscape - Currently, other PD-1/VEGF dual antibodies, such as Ivosidenib by Kangfang Biotech and PM8002 by BMS, have entered clinical Phase III, indicating a competitive market for dual-target therapies [2]. - The promising Phase II clinical data for HB0025, presented at the 2025 ESMO conference, showed good objective response rates and disease control rates, particularly in PD-L1 negative populations [2]. Group 3: Financial Investment - The company has invested approximately RMB 32.597 million in the research and development of the HB0025 project to date [3].